TARDBP and amyotrophic lateral sclerosis: In addition to the aforementioned examples, a transgenic C. elegans ALS model expressing mutant TARDBP was an initial platform for screening chemical compounds; the hits, neuroleptics, were then validated in a zebrafish model, and the most potent molecules were subsequently examined in mice and in a small clinical trial (Patten et al., 2017).